PHARMASEAL Launches Second Release of Engility CTMS
PHARMASEAL, a provider of clinical trial management and governance solutions, announces a second major release of its Engility CTMS platform. New features include site monitoring, issue management, and global access management.
With a focus on configurability and collaboration, the Engility CTMS monitoring module provides a workspace to manage all monitoring visits (onsite/remote/telephone) via an intuitive interface to support working in the system.
Commenting on the enhanced platform, Daljit Cheema, CEO and Founder of PHARMASEAL said: “Engility CTMS is a SaaS cloud platform built with agility at its core and engineered to evolve. PHARMASEALS’ collective passion for continuous innovation leads to capabilities, such as the monitoring module, so that biopharmaceutical sponsors and medical device companies of all sizes can proactively and collaboratively adopt an innovative approach.”
Flexible and scalable in order to meet the needs of all organisations, Engility CTMS enables data driven decision-making.
Further information can be found at www.pharmaseal.co
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
